Personalized Vs. Standard Duration of Dual Antiplatelet Therapy and New-generation Polymer-Free vs- Biodegradable-Polymer DES

NCT ID: NCT04135989

Last Updated: 2024-02-23

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE4
• Total Enrollment: 2106 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-01-01
• Study Completion Date: 2024-10-24

Brief Summary

New-generation metallic drug-eluting stents represent the standard of care among patients undergoing percutaneous coronary intervention (PCI). Currently, few data are available as regards to the safety and efficacy of the Cre8 amphilimus-eluting stent (Cre8 AES, Alvimedica, Instanbul, Turkey) in comparison with the biodegradable polymer everolimus-eluting stent (Synergy EES, Boston Scientific, Marlborough, MA, USA). Results from randomized trials and meta-analyses consistently indicate that prolonged dual antiplatelet therapy (DAPT) after PCI reduces ischemic events, but invariably conveys an excess of clinically relevant bleeding, which is proportional to the duration of treatment. It has been estimated, indeed, that for every non-fatal ischemic event avoided with prolonged DAPT, two or more clinically relevant bleeding events have to be expected. Given the trade-off between benefits and risks and the lack of mortality benefit in favor of prolonged DAPT, expert consensus suggests that DAPT duration should be individualized based on ischemic versus bleeding risks. At this regard, the DAPT score has been recently proposed as standardized tool to identify patients who derive benefit or lack from a prolonged course of DAPT. However, a prospective assessment of the DAPT score is lacking and whether a personalized duration of DAPT based on the DAPT score improves the net clinical benefit remains unknown.

The objective of the study is to compared the safety and the efficacy of the Cre8 AES with the Synergy EES and a personalized DAPT duration based on the DAPT score with a standard DAPT duration among patients undergoing PCI.

Detailed Description

The objective of the trial is:

i) to evaluate the efficacy and safety of the Cre8 AES vs. the Synergy EES in a broadly unselected patient population with coronary artery disease undergoing PCI; ii) to compare the safety and efficacy of a personalized DAPT duration (3-, 6-, or 24-month) guided by the application of the DAPT score with a standard DAPT duration (12-month) after PCI.

In particular, the objectives of the trial are to test the following hypothesis:

• The Cre8 AES is non-inferior to the Synergy EES with regards to a device-oriented composite endpoint (DOCE) at 1-year follow-up.
• A personalized DAPT duration based on the DAPT score is superior to a standard DAPT duration with regards to a net adverse clinical endpoint (NACE) at 2-year follow-up.

This is a prospective, randomized, multicenter, investigator-initiated, assessor-blind trial to be conducted at interventional cardiology centers in Italy. Patients undergoing PCI will be randomized in a 2-by-2 randomization fashion to undergo PCI with the Cre8 AES or Synergy EES and to receive a personalized or standard DAPT duration. All patients will be followed at 3-, 6-, 12- and 24-month after PCI for clinical endpoints.

Use of experimental and control DES:

Both the study stent (Cre8 AES) and the control stent (Synergy EES) will be used according to their indications for use. The randomly assigned stent is not expected to have an influence on the conduct of the procedure that will take place according to the routine practice. Eligible patients will undergo PCI as per local protocol, according to current guidelines of the European Society of Cardiology on myocardial revascularization. The technique of PCI (vascular access route, choice of the vascular sheath diameter, choice of the diagnostic and guiding catheters sizes and shapes, choice of the coronary guidewire) will be left to the discretion of the operator as per standard individual and local practice. The operator will choose the appropriate length and diameter of the stents to be implanted by visual estimate or quantitative coronary angiography as per local practice. The Cre8 AES and the Synergy EES systems are commercially available and all sizes may be used for the study.

DAPT duration according to randomization:

DAPT duration in patients randomized to personalized DAPT regimen: In patients that are randomized to a personalized DAPT and have a low DAPT score (<2), DAPT duration is recommended for 3 months in case of stable coronary artery disease at the time of the index procedure or for 6 months in case of acute coronary syndrome at the time of the index procedure. A low dose of aspirin (75 to 162 mg daily) will be administered throughout the course of the study. In patients that are randomized to a personalized DAPT and have a high DAPT score (≥2), DAPT duration is recommended for 24 months. Changes in the dose or in the type of P2Y12 receptor inhibitor (clopidogrel, prasugrel, or ticagrelor) are allowed during the course of the study. A low dose of aspirin (75 to 162 mg daily) will be administered throughout the course of the study. At 12-month, patients on treatment with prasugrel or ticagrelor should continue the same P2Y12 receptor inhibitor. In this specific scenario, it is preferable to continue with the same P2Y12 receptor inhibitor (prasugrel 10 mg daily or ticagrelor 90 mg daily) or to switch to a low-dose regimen of ticagrelor (60 mg twice daily) if clinically indicated or to switch to clopidogrel (75 mg daily).

DAPT regimen in patients in patients randomized to a standard DAPT duration: In patients that are randomized to a standard DAPT duration, oral P2Y12 inhibitors (clopidogrel, prasugrel, or ticagrelor) should be administered for 12-month. A low dose of aspirin (75 to 162 mg daily) will be administered throughout the course of the study.

Conditions

Coronary Artery Disease; Acute Coronary Syndrome; Chronic Coronary Syndrome; Myocardial Infarction

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: FACTORIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Cre8 AES and personalized DAPT duration

Percutaneous coronary intervention with implantation of a Cre8 amphilimus- eluting stent for coronary artery disease.

Personalized duration of dual antiplatelet therapy for 3-, 6-, or 24-month after percutaneous coronary intervention based on the DAPT score.

Group Type: OTHER

Percutaneous coronary intervention with implantation of amphilimus-eluting stents for coronary artery disease.

Intervention Type: DEVICE

Implantation of polymer-free, amphilimus-eluting, drug-eluting stents

Personalized DAPT duration

Intervention Type: DRUG

Duration of dual antiplatelet therapy according to DAPT score for 3- or 6- months in patients with low DAPT score (stable CAD or ACS, respectively) or for 24-months in patients with high DAPT score

Cre8 AES and standard DAPT duration

Percutaneous coronary intervention with implantation of a Cre8 amphilimus- eluting stent for coronary artery disease.

Standard duration of dual antiplatelet therapy for 12-month after percutaneous coronary intervention.

Group Type: OTHER

Percutaneous coronary intervention with implantation of amphilimus-eluting stents for coronary artery disease.

Intervention Type: DEVICE

Implantation of polymer-free, amphilimus-eluting, drug-eluting stents

Standard DAPT duration

Intervention Type: DRUG

Duration of dual antiplatelet therapy for 12 months.

Synergy EES and personalized DAPT duration

Percutaneous coronary intervention with implantation of a Synergy everolimus-eluting stent for coronary artery disease.

Personalized duration of dual antiplatelet therapy for 3-, 6-, or 24-month after percutaneous coronary intervention based on the DAPT score.

Group Type: OTHER

Percutaneous coronary intervention with implantation of everolimus-eluting stents for coronary artery disease.

Intervention Type: DEVICE

Implantation of biodegradable-polymer, everolimus-eluting, drug-eluting stents

Personalized DAPT duration

Intervention Type: DRUG

Duration of dual antiplatelet therapy according to DAPT score for 3- or 6- months in patients with low DAPT score (stable CAD or ACS, respectively) or for 24-months in patients with high DAPT score

Synergy EES and standard DAPT duration

Percutaneous coronary intervention with implantation of a Synergy everolimus-eluting stent for coronary artery disease.

Standard duration of dual antiplatelet therapy for 12-month after percutaneous coronary intervention.

Group Type: OTHER

Percutaneous coronary intervention with implantation of everolimus-eluting stents for coronary artery disease.

Intervention Type: DEVICE

Implantation of biodegradable-polymer, everolimus-eluting, drug-eluting stents

Standard DAPT duration

Intervention Type: DRUG

Duration of dual antiplatelet therapy for 12 months.

Interventions

Percutaneous coronary intervention with implantation of amphilimus-eluting stents for coronary artery disease.

Implantation of polymer-free, amphilimus-eluting, drug-eluting stents

Intervention Type: DEVICE

Percutaneous coronary intervention with implantation of everolimus-eluting stents for coronary artery disease.

Implantation of biodegradable-polymer, everolimus-eluting, drug-eluting stents

Intervention Type: DEVICE

Personalized DAPT duration

Duration of dual antiplatelet therapy according to DAPT score for 3- or 6- months in patients with low DAPT score (stable CAD or ACS, respectively) or for 24-months in patients with high DAPT score

Intervention Type: DRUG

Standard DAPT duration

Duration of dual antiplatelet therapy for 12 months.

Intervention Type: DRUG

Other Intervention Names

Cre8 AES; Synergy EES

Eligibility Criteria

Inclusion Criteria

1. Age ≥18 years;

2. Clinical evidence of coronary artery disease requiring PCI with DES implantation;

3. Any coronary lesion sized 2.25-4.5 mm by visual estimation.

Exclusion Criteria

1. Inability to provide informed consent;

2. Active bleeding requiring medical attention (BARC ≥2);

3. Need for chronic oral anticoagulant therapy;

4. Planned surgery within 3 months;

5. Known hypersensitivity or allergy to aspirin or any P2Y12 receptor inhibitor (clopidogrel, prasugrel, ticagrelor), heparin, contrast agent, or any DES-components;

6. Previous treatment with bioresorbable vascular scaffolds;

7. Participation in another study that has not reached the primary endpoint;

8. A life expectancy of less than 24 months;

9. Female of childbearing potential;

10. Under judicial protection, tutorship or curatorship.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

AdvicePharma Group

UNKNOWN

Sponsor Role: collaborator

Federico II University

OTHER

Sponsor Role: lead

Responsible Party

Giovanni Esposito

Professor of Cardiology

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Casa di Cura Villa Dei Fiori

Acerra, Naples, Italy

Ospedale S.Maria delle Grazie

Pozzuoli, Naples, Italy

Ospedale "Maria SS. Addolorata"

Eboli, SA, Italy

A.O.R.N. S.Giuseppe Moscati-Città Ospedaliera

Avellino, , Italy

Ospedale San Giuseppe Moscati

Aversa, , Italy

A.O.R.N. Sant'Anna e San Sebastiano

Caserta, , Italy

Ospedale San Giuliano

Giugliano in Campania, , Italy

Federico II University of Naples

Naples, , Italy

A.O.R.N. A. Cardarelli

Napoli, , Italy

Ospedale San Giovanni Bosco - ASL Napoli 1

Napoli, , Italy

Ospedale del Mare

Napoli, , Italy

Ospedale Santa Maria della Pietà

Nola, , Italy

AOU San Giovanni di Dio e Ruggi d'Aragona

Salerno, , Italy

Countries

Italy

References

Piccolo R, Windecker S. Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: A Tale of 2 Decades With New Perspectives in the Era of New-Generation Drug-Eluting Stents. Circ Cardiovasc Interv. 2016 Feb;9(2):e003587. doi: 10.1161/CIRCINTERVENTIONS.116.003587. No abstract available.

Reference Type: BACKGROUND

PMID: 26858081 (View on PubMed)

Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Juni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN; ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018 Jan 14;39(3):213-260. doi: 10.1093/eurheartj/ehx419. No abstract available.

Reference Type: BACKGROUND

PMID: 28886622 (View on PubMed)

Spencer FA, Prasad M, Vandvik PO, Chetan D, Zhou Q, Guyatt G. Longer- Versus Shorter-Duration Dual-Antiplatelet Therapy After Drug-Eluting Stent Placement: A Systematic Review and Meta-analysis. Ann Intern Med. 2015 Jul 21;163(2):118-26. doi: 10.7326/M15-0083.

Reference Type: BACKGROUND

PMID: 26005909 (View on PubMed)

Bittl JA, Baber U, Bradley SM, Wijeysundera DN. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016 Sep 6;68(10):1116-39. doi: 10.1016/j.jacc.2016.03.512. Epub 2016 Mar 29.

Reference Type: BACKGROUND

PMID: 27036919 (View on PubMed)

Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA, Mack MJ, Mauri L, Mehran R, Mukherjee D, Newby LK, O'Gara PT, Sabatine MS, Smith PK, Smith SC Jr. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016 Sep 6;68(10):1082-115. doi: 10.1016/j.jacc.2016.03.513. Epub 2016 Mar 29. No abstract available.

Reference Type: BACKGROUND

PMID: 27036918 (View on PubMed)

Raber L, Piccolo R. CardioPulse: Different bleeding scores and which one should we use? Eur Heart J. 2016 Jan 21;37(4):327-31. No abstract available.

Reference Type: BACKGROUND

PMID: 27462674 (View on PubMed)

Yeh RW, Secemsky EA, Kereiakes DJ, Normand SL, Gershlick AH, Cohen DJ, Spertus JA, Steg PG, Cutlip DE, Rinaldi MJ, Camenzind E, Wijns W, Apruzzese PK, Song Y, Massaro JM, Mauri L; DAPT Study Investigators. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA. 2016 Apr 26;315(16):1735-49. doi: 10.1001/jama.2016.3775.

Reference Type: BACKGROUND

PMID: 27022822 (View on PubMed)

Piccolo R, Gargiulo G, Franzone A, Santucci A, Ariotti S, Baldo A, Tumscitz C, Moschovitis A, Windecker S, Valgimigli M. Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention. Ann Intern Med. 2017 Jul 4;167(1):17-25. doi: 10.7326/M16-2389. Epub 2017 Jun 13.

Reference Type: BACKGROUND

PMID: 28605779 (View on PubMed)

Rozemeijer R, Stein M, Voskuil M, van den Bor R, Frambach P, Pereira B, Koudstaal S, Leenders GE, Timmers L, Rittersma SZ, Kraaijeveld AO, Agostoni P, Roes KC, Doevendans PA, Stella PR; ReCre8 Study Investigators. Randomized All-Comers Evaluation of a Permanent Polymer Zotarolimus-Eluting Stent Versus a Polymer-Free Amphilimus-Eluting Stent. Circulation. 2019 Jan 2;139(1):67-77. doi: 10.1161/CIRCULATIONAHA.118.037707.

Reference Type: BACKGROUND

PMID: 30586704 (View on PubMed)

Navarese EP, Andreotti F, Schulze V, Kolodziejczak M, Buffon A, Brouwer M, Costa F, Kowalewski M, Parati G, Lip GY, Kelm M, Valgimigli M. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ. 2015 Apr 16;350:h1618. doi: 10.1136/bmj.h1618.

Reference Type: BACKGROUND

PMID: 25883067 (View on PubMed)

Garcia-Garcia HM, McFadden EP, Farb A, Mehran R, Stone GW, Spertus J, Onuma Y, Morel MA, van Es GA, Zuckerman B, Fearon WF, Taggart D, Kappetein AP, Krucoff MW, Vranckx P, Windecker S, Cutlip D, Serruys PW; Academic Research Consortium. Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. Circulation. 2018 Jun 12;137(24):2635-2650. doi: 10.1161/CIRCULATIONAHA.117.029289.

Reference Type: BACKGROUND

PMID: 29891620 (View on PubMed)

Piccolo R, Calabro P, Carrara G, Simonetti F, Varricchio A, Attisano T, Napolitano G, De Simone C, Carpinella G, Stabile E, Cirillo P, Di Serafino L, Caiazzo G, Tesorio T, Boccalatte M, Tuccillo B, Avvedimento M, Leone A, Galasso G, Cesaro A, Perrotta R, Niglio T, Castiello DS, Immobile Molaro M, Bardi L, Spinelli A, Cristiano S, Bellino M, Leonardi S, Biscaglia S, Costa F, Cassese S, McFadden E, Heg D, Stefanini GG, Franzone A, Capodanno D, Esposito G; PARTHENOPE Study Group. Personalized or Standard Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: The PARTHENOPE Randomized Trial. J Am Coll Cardiol. 2025 Aug 30:S0735-1097(25)07548-5. doi: 10.1016/j.jacc.2025.08.040. Online ahead of print.

Reference Type: DERIVED

PMID: 40892607 (View on PubMed)

Piccolo R, Calabro P, Carrara G, Varricchio A, Baldi C, Napolitano G, De Simone C, Mauro C, Stabile E, Caiazzo G, Tesorio T, Boccalatte M, Tuccillo B, Cirillo P, Di Serafino L, Simonetti F, Leone A, Angellotti D, Bottiglieri G, Russolillo E, Galasso G, Perrotta R, Cesaro A, Niglio T, Capasso M, Spinelli A, Cristiano S, Faretra A, Bruzzese D, Chieffo A, Tarantini G, Leonardi S, Biscaglia S, Costa F, Cassese S, McFadden E, Heg D, Franzone A, Stefanini GG, Capodanno D, Esposito G, Parthenope Investigators FT. Polymer-free versus biodegradable-polymer drug-eluting stent in patients undergoing percutaneous coronary intervention: an assessor-blind, non-inferiority, randomised controlled trial. EuroIntervention. 2025 Jan 6;21(1):58-72. doi: 10.4244/EIJ-D-24-00657.

Reference Type: DERIVED

PMID: 39773824 (View on PubMed)

Piccolo R, Calabro P, Varricchio A, Baldi C, Napolitano G, De Simone C, Mauro C, Stabile E, Caiazzo G, Tesorio T, Boccalatte M, Tuccillo B, Bottiglieri G, Russolillo E, Di Lorenzo E, Carrara G, Cassese S, Leonardi S, Biscaglia S, Costa F, McFadden E, Heg D, Franzone A, Stefanini GG, Capodanno D, Esposito G. Rationale and design of the PARTHENOPE trial: A two-by-two factorial comparison of polymer-free vs biodegradable-polymer drug-eluting stents and personalized vs standard duration of dual antiplatelet therapy in all-comers undergoing PCI. Am Heart J. 2023 Nov;265:153-160. doi: 10.1016/j.ahj.2023.08.001. Epub 2023 Aug 10.

Reference Type: DERIVED

PMID: 37572785 (View on PubMed)

Other Identifiers

197/19

Identifier Type: -

Identifier Source: org_study_id